21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
18:48 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

4-1BBL fusion protein boosts T cell bispecific Abs for gastric cancer and lymphoma

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer; lymphoma Tumor-targeted 4-1BBL fusion proteins could enhance the efficacy of T cell bispecific antibodies to treat gastric cancer and lymphoma. The fusion proteins consist of a trimer of the...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
22:17 , May 24, 2019 |  BC Extra  |  Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

Cytokine mimics permit control of dimer receptor signaling  David Baker and Christopher Garcia's University of Washington-Stanford University team has created cytokine mimetics -- symmetric compounds for tunable control of cytokine receptor signaling. In a proof-of-concept...
19:53 , May 2, 2019 |  BC Extra  |  Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
14:35 , Apr 1, 2019 |  BC Extra  |  Clinical News

MSKCC CAR T shows 72% response in mesothelioma

Researchers from MSKCC presented data for a mesothelin-targeted autologous CAR T cell therapy that could be the first to crack the solid tumor juggernaut for this treatment modality while also minimizing toxicity. The data could...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...